Latest Insider Transactions at Bei Gene, Ltd. (BGNE)
This section provides a real-time view of insider transactions for Bei Gene, Ltd. (BGNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BeiGene, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BeiGene, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 26
2025
|
Corazon (Corsee) D. Sanders Director |
SELL
Open market or private sale
|
Direct |
2,627
-84.7%
|
$895,807
$341.34 P/Share
|
|
Nov 26
2025
|
Corazon (Corsee) D. Sanders Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,627
+50.0%
|
$417,693
$159.03 P/Share
|
|
Nov 17
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
3,991
-92.62%
|
$1,520,571
$381.25 P/Share
|
|
Nov 13
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
6,009
-85.28%
|
$2,283,420
$380.69 P/Share
|
|
Nov 12
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
10,000
-10.14%
|
$3,550,000
$355.43 P/Share
|
|
Nov 12
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
996
-83.33%
|
$347,604
$349.38 P/Share
|
|
Nov 12
2025
|
Chan Henry Lee SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
996
+36.39%
|
$187,248
$188.94 P/Share
|
|
Nov 12
2025
|
John Oyler Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
858,533
-11.76%
|
-
|
|
Nov 11
2025
|
John Oyler Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
151,320
-2.03%
|
-
|
|
Nov 07
2025
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
424,073
-8.47%
|
-
|
|
Oct 08
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
10,671
-65.04%
|
$3,724,179
$349.79 P/Share
|
|
Oct 08
2025
|
Chan Henry Lee SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
9,559
+34.06%
|
$1,797,092
$188.94 P/Share
|
|
Sep 16
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
27,803
-61.68%
|
$9,063,778
$326.0 P/Share
|
|
Sep 10
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
10,006
-74.35%
|
$3,261,956
$326.13 P/Share
|
|
Sep 10
2025
|
Chan Henry Lee SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,894
+23.5%
|
$1,672,072
$188.94 P/Share
|
|
Sep 09
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
5,000
-100.0%
|
$1,750,000
$350.06 P/Share
|
|
Sep 09
2025
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
148,096
-2.87%
|
-
|
|
Sep 05
2025
|
Corazon (Corsee) D. Sanders Director |
SELL
Open market or private sale
|
Direct |
2,665
-100.0%
|
$898,105
$337.0 P/Share
|
|
Sep 05
2025
|
Corazon (Corsee) D. Sanders Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,665
+50.0%
|
$413,075
$155.68 P/Share
|
|
Sep 02
2025
|
Titus B. Ball Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
122
-100.0%
|
$39,772
$326.76 P/Share
|
|
Aug 14
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
39,936
-41.08%
|
$12,140,544
$304.7 P/Share
|
|
Aug 14
2025
|
Xiaobin Wu President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,936
+34.35%
|
$6,269,952
$157.35 P/Share
|
|
Aug 13
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
49,858
-29.51%
|
$15,106,974
$303.99 P/Share
|
|
Aug 13
2025
|
Xiaobin Wu President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
49,858
+42.6%
|
$8,226,570
$165.05 P/Share
|
|
Aug 13
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
11,013
-91.18%
|
$3,303,900
$300.4 P/Share
|
|
Aug 13
2025
|
Chan Henry Lee SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,230
+40.93%
|
$1,448,480
$176.75 P/Share
|
|
Aug 01
2025
|
Aaron Rosenberg Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,190
-100.0%
|
$345,100
$290.47 P/Share
|
|
Jul 30
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
259
-100.0%
|
$78,995
$305.0 P/Share
|
|
Jul 30
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
920
-100.0%
|
$279,680
$304.6 P/Share
|
|
Jul 29
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
4,041
-55.25%
|
$1,224,423
$303.03 P/Share
|
|
Jul 18
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
700
-100.0%
|
$210,000
$300.0 P/Share
|
|
Jul 09
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
27,802
-63.75%
|
$7,033,906
$253.58 P/Share
|
|
Jun 24
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
2,007
-65.73%
|
$531,855
$265.81 P/Share
|
|
Jun 23
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,028
-100.0%
|
$267,280
$260.0 P/Share
|
|
Jun 23
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,174
-98.42%
|
$831,588
$262.24 P/Share
|
|
Jun 23
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,363
-100.0%
|
$354,380
$260.0 P/Share
|
|
Jun 17
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
470
-100.0%
|
$117,970
$251.37 P/Share
|
|
Jun 17
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,460
-100.0%
|
$373,760
$256.49 P/Share
|
|
Jun 17
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
630
-100.0%
|
$157,500
$250.87 P/Share
|
|
Jun 16
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,177
-71.46%
|
$313,082
$266.4 P/Share
|
|
Jun 16
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
422
-100.0%
|
$112,252
$266.5 P/Share
|
|
Jun 16
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,680
-71.6%
|
$978,880
$266.05 P/Share
|
|
Jun 16
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,543
-40.05%
|
$408,895
$265.85 P/Share
|
|
Jun 11
2025
|
Titus B. Ball Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
134
-100.0%
|
$34,572
$258.36 P/Share
|
|
Jun 10
2025
|
Titus B. Ball Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,601
+28.58%
|
-
|
|
Jun 10
2025
|
Aaron Rosenberg Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,674
+21.62%
|
-
|
|
Jun 10
2025
|
Chan Henry Lee SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
46,878
+14.17%
|
-
|
|
Jun 10
2025
|
Xiaobin Wu President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
123,370
+8.83%
|
-
|
|
Jun 10
2025
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
86,359
+7.54%
|
-
|
|
Jun 10
2025
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,055
+2.19%
|
-
|